LONGEVERON INC.

Profile

Company Names

LONGEVERON INC.
LONGEVERON LLC

Addresses

1951 NW 7TH AVENUE, SUITE 520, MIAMI, FL 33136

1951 NW 7TH AVE., SUITE 520, MIAMI, FL 33136

Phone Numbers

305-302-7158
305-909-0840

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

> 5 years ago

State Incorporated:

DELAWARE

Total Amount Raised:

$37,407,515.00

Number of Funding Rounds:

9
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
9
2026-03-11 
$15,890,000.00 
$33,515,000.00 
$17,625,000.00 
Equity 
8
2024-07-19 
$0.00 
$9,508,010.00 
$9,508,010.00 
 
7
2024-06-18 
$0.00 
$9,444,516.00 
$9,444,516.00 
 
6
2024-04-18 
$0.00 
$12,424,674.00 
$12,424,674.00 
 
5
2023-12-22 
$0.00 
$2,571,942.00 
$2,571,942.00 
 
4
2023-10-13 
$0.00 
$8,350,001.00 
$8,350,001.00 
 
3
2021-12-03 
$20,462,545.00 
$20,462,545.00 
$0.00 
Equity 
2
2020-01-22 
$100,000.00 
$25,000,000.00 
$24,900,000.00 
Equity 
1
2017-10-20 
$954,970.00 
$25,000,000.00 
$24,045,030.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
NATALIYA 
 
AGAFONOVA 
EXECUTIVE OFFICER
KHOSO 
 
BALUCH 
DIRECTOR
DEVIN 
 
BLASS 
EXECUTIVE OFFICER
ERIN 
 
BORGER 
DIRECTOR
JAMES 
 
CLAVIJO 
EXECUTIVE OFFICER
GEOFF 
 
GREEN 
EXECUTIVE OFFICER
ROGER 
JOSEPH 
HAJJAR 
DIRECTOR
JOSHUA 
 
HARE 
EXECUTIVE OFFICER, DIRECTOR
JOSHUA 
M. 
HARE 
EXECUTIVE OFFICER, DIRECTOR, PROMOTER
NEIL 
 
HARE 
DIRECTOR
NEIL 
E. 
HARE 
DIRECTOR
WA-EL 
 
HASHAD 
EXECUTIVE OFFICER, DIRECTOR
RICHARD 
 
KENDER 
DIRECTOR
PAUL 
 
LEHR 
EXECUTIVE OFFICER
LISA 
 
LOCKLEAR 
EXECUTIVE OFFICER
LISA 
A. 
LOCKLEAR 
EXECUTIVE OFFICER
DOUGLAS 
 
LOSORDO 
DIRECTOR
NEHA 
J. 
MOTWANI 
DIRECTOR
SUZANNE 
 
PAGE 
EXECUTIVE OFFICER
GEORGE 
 
PALETTA, JR. 
DIRECTOR
JEFFREY 
 
PFEFFER 
DIRECTOR
CATHY 
 
ROSS 
DIRECTOR
DONALD 
 
SOFFER 
DIRECTOR
DONALD 
M. 
SOFFER 
DIRECTOR
ROCK 
 
SOFFER 
DIRECTOR
URSULA 
 
UNGARO 
DIRECTOR
STEPHEN 
H. 
WILLARD 
EXECUTIVE OFFICER
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2026-03-11 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2024-07-19 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2024-06-18 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2024-04-18 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2023-12-22 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2023-10-13 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2021-12-03 
D/A
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2017-10-20 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2020-01-22 
D/A
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2017-10-20 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2017-10-20 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
CHARLES WORTHMAN
H.C. WAINWRIGHT + CO., LLC
375
NOAM RUBINSTEIN
H.C. WAINWRIGHT + CO., LLC
375
CRAIG SCHWABE
H.C. WAINWRIGHT + CO., LLC
375
MICHAEL VASINKEVICH
H.C. WAINWRIGHT + CO., LLC
375
CHARLES WORTHMAN
H.C. WAINWRIGHT + CO., LLC
375
NONE
NONE
EF HUTTON, DIVISION OF BENCHMARK INVESTMENTS, LLC